The FDA's approval of Actavis' generic Adderall XR will be a positive for Watson Pharmaceuticals...

|By:, SA News Editor

The FDA's approval of Actavis' generic Adderall XR will be a positive for Watson Pharmaceuticals (WPI +1%), which is acquiring the company, says Goldman. The firm says the news supports its above consensus earnings estimates, adding that it sees only modest impact to TEVA and IPXL.